Corbus Pharmaceuticals will present results showing that Resunab (JBT-101), the company’s cannabis-derived treatment for systemic sclerosis (SSc), can trigger specific…
Articles by Patrícia Silva, PhD
The U.S. Food and Drug Administration (FDA) has granted Cytori Therapeutics Small Business status for fiscal year 2017, which means Cytori…
Cytori Therapeutics will expand the development of its ECCS-50 scleroderma treatment to include secondary Raynaud’s phenomenon (RP), under the…
Protagen has launched NavigAID SSc, a new disease stratification assay that, by measuring serum biomarkers, can define specific systemic sclerosis…
At its 12th Annual Cool Comedy – Hot Cuisine gala in New York, the Scleroderma Research Foundation (SRF)…
Cytori Therapeutics recently published two-year clinical follow-up data of its SCLERADEC-I pilot trial showing that a single administration of the company’s …
Preliminary data of Cytori Therapeutics’ STAR Phase 3 trial (NCT02396238) demonstrated that the company’s adipose-derived regenerative cells (ADRCs)…
Protagen AG and Inova Diagnostics have signed a semi-exclusive license agreement for BICD2, a new autoantigen and the…
A new clinical trial assessing neuropsychiatric complications in patients with systemic sclerosis — like depression and cognitive problems — is starting in…
iBio recently announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to iBio-CFB03 for the treatment of…